Technical Data Sheet

InVivoSIM anti-human VEGF (Bevacizumab Biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIM0007**
Clone:	**Bevacizumab**
Isotype:	Human IgG1
Recommended Isotype Control(s):	RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Immunogen:	Human VEGF
Reported Applications:	VEGF neutralization Flow Cytometry ELISA Immunoprecipitation Western Block
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/µg) Determined by LAL gel clotting assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 µm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
Aggregation:	<5% Determined by SEC
RRID:	AB_2894728
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research use. This Bevacizumab biosimilar reacts with human VEGF (vascular endothelial growth factor). VEGF is a 45 kDa homodimeric, disulfide-linked glycoprotein that plays key roles in angiogenesis, vasculogenesis, and endothelial cell growth. It promotes mitogenesis, chemotaxis, and vascular permeability. Most tumors have a requirement for angiogenesis, and inhibition of VEGF biding to VEGF receptors has been the focus of several tumor therapeutic strategies.

Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the inhibition of tumor growth.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information


Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/sim0007?bxcs=9k1b3a#tab_references or scan the QR code below.

Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail technicalservice@bioxcell.com.



Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC